DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Stallmach A, Langbein C, Atreya R. et al.
Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study.
Aliment Pharmacol Ther 2016;
44: 1199-1212
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.